Universal Technical Institute
UTI
$27.87
-34.22%
Universal Technical Institute, Inc. (UTI) is a leading provider of postsecondary education and training programs for technicians in the automotive, diesel, collision repair, motorcycle, and marine industries, operating through its UTI and Concorde Career Colleges segments. As a specialized educational institution with a strong brand portfolio including Motorcycle Mechanics Institute and Marine Mechanics Institute, it holds a distinct niche in skilled trades training. The current investor narrative centers on UTI's accelerating enrollment growth and margin expansion, driven by strong demand for skilled trades workers and successful strategic initiatives, though recent stock volatility has raised questions about valuation sustainability.…
UTI
Universal Technical Institute
$27.87
Investment Opinion: Should I buy UTI Today?
Rating: Hold. UTI's strong enrollment growth and favorable industry tailwinds are offset by deteriorating margins, negative free cash flow, and a premium valuation. The analyst consensus is Buy with an average target of $43.67, but the recent earnings weakness and high forward P/E warrant caution.
Supporting Evidence: Revenue grew 6.7% YoY to $221.4M, but net income collapsed 96% to $0.4M. The trailing P/E of 28.1x is above the industry average of ~20x, while the forward P/E of 43.4x implies aggressive growth expectations. ROE of 19.2% is strong, but negative free cash flow raises concerns about sustainability. The average analyst target of $43.67 offers only 8.3% upside, and the low target of $38.00 suggests downside risk.
Risks & Conditions: The Hold rating would upgrade to Buy if UTI demonstrates margin recovery (operating margin above 5%) and positive free cash flow in the next two quarters, or if the stock pulls back to the $35 level, offering a better entry. It would downgrade to Sell if revenue growth decelerates below 5% or if the company reports a net loss. Overall, UTI appears overvalued relative to its near-term earnings power, but fairly valued on a long-term growth basis if margins normalize.
Sign up to view all
UTI 12-Month Price Forecast
UTI's investment case is balanced. The company benefits from strong secular demand for skilled trades, but near-term financial performance is weak, with margins contracting and free cash flow negative. The stock's premium valuation leaves it vulnerable to any disappointment. The neutral stance reflects the tension between positive long-term trends and near-term execution risks. An upgrade to bullish would require evidence of margin stabilization and positive FCF, while a downgrade to bearish would follow further deterioration in earnings or a broader market sell-off.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Universal Technical Institute's 12-month outlook, with a consensus price target around $42.17 and implied upside of +51.3% versus the current price.
Average Target
$42.17
0 analysts
Implied Upside
+51.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$38 - $49
Analyst target range
Six analysts cover UTI, with a consensus leaning bullish: all recent ratings are Buy or Outperform, and no Hold or Sell ratings are reported. The average target price is $43.67, implying 8.3% upside from the current price of $40.33. The target range spans from $38.00 (low) to $49.00 (high), indicating a spread of $11.00 or 27% of the average target, reflecting moderate uncertainty. The high target of $49.00 assumes continued enrollment growth and margin expansion, while the low target of $38.00 factors in potential competitive pressures or economic headwinds. Recent analyst actions show consistent bullishness, with Truist Securities reiterating a Buy on June 29, 2026, and Rosenblatt and Barrington Research maintaining Buy/Outperform ratings in May 2026. The lack of downgrades supports a positive sentiment, but the wide target spread suggests that the stock's trajectory is highly dependent on execution.
Bulls vs Bears: UTI Investment Factors
UTI presents a compelling growth story driven by strong enrollment trends and a favorable skilled trades labor market, supported by a unanimous analyst Buy consensus and an average target implying 8.3% upside. However, the sharp decline in Q2 net income and margins, negative free cash flow, and a forward P/E of 43.4x raise concerns about valuation sustainability and near-term profitability. The bull case rests on continued revenue acceleration and margin recovery, while the bear case hinges on cost pressures and potential earnings disappointment. The single most important tension is whether UTI can restore operating margins to historical levels (around 10%) while sustaining enrollment growth; if margins recover, the stock could re-rate higher, but if they remain compressed, the premium valuation may unwind.
Bullish
- Strong Enrollment Growth Driving Revenue: Revenue grew 6.7% YoY to $221.4M in Q2 FY2026, with TTM revenue accelerating from $196.4M to $222.4M. This reflects robust demand for skilled trades training, a structural tailwind as the U.S. faces a technician shortage.
- High ROE and Improving Profitability: ROE stands at 19.2%, well above the cost of equity, indicating efficient capital use. TTM net margin of 7.5% and net income of $43.3M show the company is consistently profitable, a turnaround from prior years.
- Analyst Consensus Bullish with Upside: All six analysts rate UTI as Buy/Outperform, with an average target of $43.67 (8.3% upside) and a high target of $49.00 (21.5% upside). Recent reiterations by Truist, Rosenblatt, and Barrington signal confidence in the growth story.
- Favorable Industry Tailwinds: The skilled trades labor gap is widening, with the U.S. Bureau of Labor Statistics projecting over 100,000 annual openings for automotive technicians. UTI's specialized programs position it to capture this demand, supporting enrollment growth.
Bearish
- Sharp Decline in Net Income and Margins: Net income fell from $11.4M to $0.4M YoY in Q2 FY2026, and gross margin contracted from 50.6% to 46.7%. Operating margin dropped to 0.2%, suggesting cost pressures or investment spending that may not yield immediate returns.
- Negative Free Cash Flow and High Leverage: Free cash flow was -$26.4M in Q2 FY2026, and TTM FCF is only $1.4M. Debt-to-equity of 0.85 and a current ratio of 1.07 indicate limited financial flexibility, which could constrain growth or lead to dilution.
- Expensive Valuation on Forward Earnings: Forward P/E of 43.4x is a premium to the industry average (~20x) and implies the market expects significant earnings acceleration. If growth disappoints, multiple compression could be severe.
- High Beta and Recent Volatility: Beta of 1.226 makes UTI 22.6% more volatile than the market. The 13.5% single-day drop on July 15, 2026, from $46.65 to $40.33, highlights vulnerability to profit-taking or negative news.
UTI Technical Analysis
UTI is in a sustained uptrend, with the stock up 26.3% over the past year and currently trading at $40.33, which is 78.6% of its 52-week range ($21.29 to $51.34). The price sits well above the midpoint, indicating strong bullish momentum, though it has pulled back from the July high of $51.20, suggesting potential overextension near the top of the range. The 52-week low of $21.29 provides a clear support level, while the high of $51.34 represents resistance. Short-term momentum shows a 1-month gain of 9.9% and a 3-month gain of 7.3%, both positive but decelerating from the 6-month gain of 46.7%. The 1-month relative strength of 9.3% versus SPY's 0.6% indicates strong recent outperformance, but the sharp 13.5% single-day drop on July 15 suggests a potential trend reversal or profit-taking. The 1-year relative strength of 5.4% confirms the longer-term outperformance. Key support is at the 52-week low of $21.29, while resistance is at the 52-week high of $51.34. A breakout above $51.34 would signal a continuation of the uptrend, while a breakdown below $21.29 would indicate a bearish reversal. With a beta of 1.226, UTI is 22.6% more volatile than the market, meaning larger price swings and higher risk for position sizing.
Beta
1.24
1.24x market volatility
Max Drawdown
-45.6%
Largest decline past year
52-Week Range
$21-$51
Price range past year
Annual Return
-16.6%
Cumulative gain past year
| Period | UTI Return | S&P 500 |
|---|---|---|
| 1m | -45.6% | +2.8% |
| 3m | -22.0% | +4.2% |
| 6m | +9.2% | +11.3% |
| 1y | -16.6% | +21.5% |
| ytd | +12.2% | +12.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTI Fundamental Analysis
Revenue has been steadily growing, with the most recent quarter (Q2 FY2026, ending March 31, 2026) reporting $221.4 million, up 6.7% year-over-year from $207.4 million in the prior-year quarter. The trailing twelve-month revenue trend shows acceleration from $196.4 million in Q4 FY2024 to $222.4 million in Q4 FY2025, indicating consistent demand. Revenue is driven by the Postsecondary Education segment ($106.8 million in the latest quarter) and Other Segments ($3.8 million), with the UTI brand contributing the majority. The growth trajectory supports the investment case as skilled trades demand remains robust. Profitability has improved significantly, with net income of $0.4 million in Q2 FY2026 versus $11.4 million in the prior-year quarter, a sharp decline due to higher operating expenses. Gross margin was 46.7% in Q2 FY2026, down from 50.6% a year ago, indicating margin compression. However, the trailing twelve-month net margin is 7.5%, and the company has been profitable for the past several quarters, with net income of $18.8 million in Q4 FY2025. The operating margin of 0.2% in Q2 FY2026 is low but reflects seasonal and investment-related costs. The balance sheet shows a debt-to-equity ratio of 0.85, indicating moderate leverage, and a current ratio of 1.07, suggesting adequate liquidity. Free cash flow was negative $26.4 million in Q2 FY2026, but the trailing twelve-month free cash flow is $1.4 million, barely positive. ROE is 19.2%, indicating strong returns on equity, but the negative free cash flow raises concerns about reliance on external financing for growth investments.
Quarterly Revenue
$221402000.0B
2026-03
Revenue YoY Growth
+6.7%
YoY Comparison
Gross Margin
46.7%
Latest Quarter
Free Cash Flow
$1441000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTI Overvalued?
Since net income is positive (TTM net income of $43.3 million), the primary valuation metric is the P/E ratio. The trailing P/E is 28.1x, while the forward P/E is 43.4x, implying the market expects lower earnings growth in the near term. The gap between trailing and forward P/E suggests that earnings are expected to decline, which is a bearish signal. Compared to the industry average (Education & Training Services), UTI's P/E of 28.1x is at a premium, as the sector typically trades at lower multiples due to regulatory risks and cyclical enrollment. The P/S ratio of 2.1x is also elevated versus the industry average of around 1.5x, indicating a premium valuation. Historically, UTI's trailing P/E has ranged from 7.8x (Q1 FY2022) to over 1,000x (Q2 FY2026 due to low earnings), so the current 28.1x is near the lower end of its recent range, suggesting it is not excessively overvalued relative to its own history. However, the forward P/E of 43.4x is above the historical average, implying the market is pricing in optimistic future growth.
PE
28.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 8x~70x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
13.1x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: UTI's financial health is under strain. Net income plummeted 96% YoY to $0.4M in Q2 FY2026, and gross margin fell from 50.6% to 46.7%. Operating margin was a razor-thin 0.2%, indicating that rising costs (SGA up 17.6% YoY) are outpacing revenue growth. Free cash flow was negative $26.4M in the quarter, and TTM FCF is only $1.4M, barely positive. With a debt-to-equity ratio of 0.85 and current ratio of 1.07, the company has limited liquidity buffer, making it vulnerable to any further margin compression or unexpected cash needs. The reliance on continued enrollment growth to cover fixed costs is a key risk; any slowdown could quickly erode profitability.
Market & Competitive Risks: UTI trades at a forward P/E of 43.4x, a significant premium to the education sector average of ~20x, leaving little room for error. The stock's beta of 1.226 means it is highly correlated with market moves, and the 13.5% single-day drop on July 15 demonstrates how quickly sentiment can shift. Competition from community colleges and online vocational programs could pressure enrollment and pricing. Regulatory risks include potential changes to Title IV funding or accreditation requirements, which could impact revenue. The wide analyst target range ($38-$49) reflects uncertainty about the sustainability of growth.
Worst-Case Scenario: If enrollment growth decelerates due to economic weakness or increased competition, and margins fail to recover, UTI could see its valuation compress. The 52-week low of $21.29 represents a potential downside of 47.2% from the current price of $40.33. In a severe recession, the stock could revisit that level, especially if the company reports negative earnings. The historical max drawdown of -37.37% (from the 52-week high of $51.34 to the low of $21.29) provides a reference for the worst-case loss, which would be approximately -47% from current levels to the 52-week low.
FAQ
The primary risks are: 1) Financial risk: Net income collapsed 96% YoY to $0.4M, and free cash flow was negative $26.4M in Q2 FY2026, indicating potential liquidity issues. 2) Valuation risk: Forward P/E of 43.4x leaves little room for error; if growth slows, the stock could drop significantly. 3) Competitive risk: Community colleges and online programs offer lower-cost alternatives, which could pressure enrollment. 4) Macro risk: A recession could reduce demand for skilled trades training, and the stock's beta of 1.226 makes it more volatile than the market. The most severe risk is a sustained margin compression leading to negative earnings, which could send the stock back to its 52-week low of $21.29.
The 12-month outlook is mixed. The base case (50% probability) sees the stock trading between $38 and $44, near the analyst average target of $43.67, assuming modest revenue growth and stable margins. The bull case (25% probability) targets $45-$51, driven by margin recovery and positive free cash flow. The bear case (25% probability) sees the stock falling to $21-$35, if enrollment slows and margins deteriorate further. The most likely scenario is the base case, but the wide target range reflects high uncertainty. Key assumptions include enrollment growth of 4-6% and gross margins stabilizing around 47%.
UTI appears overvalued on a near-term earnings basis. The trailing P/E of 28.1x and forward P/E of 43.4x are both above the education sector average of ~20x. The P/S ratio of 2.1x is also above the industry average of 1.5x. However, the PEG ratio of 0.55 suggests that if earnings grow as expected, the stock may be fairly valued. Historically, UTI's trailing P/E has ranged from 7.8x to over 100x, so the current 28.1x is near the lower end of its recent range, indicating it is not excessively overvalued relative to its own history. The market is pricing in optimistic future growth, and any disappointment could lead to a de-rating.
UTI offers a compelling long-term growth story driven by the skilled trades labor shortage, but near-term financials are weak. The stock trades at a forward P/E of 43.4x, which is expensive relative to the industry average of ~20x, and net income fell 96% YoY in the latest quarter. The analyst consensus is Buy with an average target of $43.67, implying 8.3% upside, but the low target of $38.00 suggests downside risk. For growth-oriented investors with a 3-5 year horizon, UTI could be a good buy on pullbacks, especially if margins stabilize. However, value-conscious investors may find the current valuation unattractive. The biggest risk is that earnings disappoint, leading to multiple compression.
UTI is better suited for long-term investment given its growth profile and volatility. The stock has a beta of 1.226, meaning it is more volatile than the market, and recent price swings (e.g., 13.5% single-day drop) make it risky for short-term trading. The company does not pay a dividend, so returns depend entirely on capital appreciation. With a forward P/E of 43.4x, the stock is priced for high growth, which may take several years to materialize. A minimum holding period of 3-5 years is recommended to allow the enrollment growth story to play out and margins to recover. Short-term traders should be cautious due to the high volatility and uncertain near-term earnings.